Structurally defined arabinogalactan (LBP-3) from Lycium barbarum have effect on improving intestinal barrier function. However, whether its intestinal barrier function depended on the changes of intestinal mucin O-glycans have not been investigated. A dextran sodium sulfate-induced acute colitis mouse model was employed to test prevention and treatment with LBP-3. The intestinal microbiota as well as colonic mucin O-glycan profiles were analyzed. Supplementation with LBP-3 inhibited harmful bacteria, including Desulfovibrionaceae, Enterobacteriaceae, and Helicobacteraceae while significantly increased the abundance of beneficial bacteria (e.g., Lachnospiraceae, Ruminococcaceae, and Lactobacillaceae). Notably, LBP-3 augmented the content of neutral O-glycans by stimulating the fucosylation glycoforms (F1H1N2 and F1H2N2), short-chain sulfated O-glycans (S1F1H1N2, S1H1N2, and S1H2N3), and sialylated medium- and long-chain O-glycans (F1H2N2A1, H2N3A1, and F1H3N2A1). In summary, we report that supplement LBP-3 significantly reduced pathological symptoms, restored the bacterial community, and promoted the expression of O-glycans to successfully prevent and alleviate colitis in a mouse model, especially in the LBP-3 prevention testing group. The underlying mechanism of action was investigated using glycomics to better clarify which the structurally defined LBP-3 were responsible for its beneficial effect against ulcerative colitis and assess its use as a functional food or pharmaceutical supplement.

枸杞中结构明确的阿拉伯半乳聚糖（LBP-3）具有改善肠道屏障功能的作用。但其肠道屏障功能是否依赖于肠道粘蛋白O-聚糖的变化尚未被研究。采用右旋糖酐硫酸钠诱导的急性结肠炎小鼠模型来测试LBP-3的预防和治疗作用。分析了肠道微生物群以及结肠粘蛋白O-聚糖谱。补充 LBP-3 可抑制有害细菌，包括脱硫弧菌科、肠杆菌科和螺杆菌科，同时显着增加有益细菌（例如毛螺菌科、瘤胃球菌科和乳杆菌科）的丰度。值得注意的是，LBP-3通过刺激岩藻糖基化糖型（F1H1N2 和 F1H2N2）、短链硫酸化O -聚糖（S1F1H1N2、S1H1N2 和 S1H2N3）以及唾液酸化中链和长链O -来增加中性 O - 聚糖的含量。聚糖（F1H2N2A1、H2N3A1 和 F1H3N2A1）。总之，我们报告补充LBP-3显着减轻病理症状，恢复细菌群落，并促进O-聚糖的表达，成功预防和缓解小鼠模型中的结肠炎，特别是在LBP-3预防测试组中。使用糖组学研究了潜在的作用机制，以更好地阐明结构确定的 LBP-3 对其对抗溃疡性结肠炎的有益作用负责，并评估其作为功能性食品或药物补充剂的用途。